| UniProt ID | CCNK_HUMAN | |
|---|---|---|
| UniProt AC | O75909 | |
| Protein Name | Cyclin-K | |
| Gene Name | CCNK | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 580 | |
| Subcellular Localization | Nucleus . | |
| Protein Description | Regulatory subunit of cyclin-dependent kinases that mediates activation of target kinases. Plays a role in transcriptional regulation via its role in regulating the phosphorylation of the C-terminal domain (CTD) of the large subunit of RNA polymerase II (POLR2A).. | |
| Protein Sequence | MKENKENSSPSVTSANLDHTKPCWYWDKKDLAHTPSQLEGLDPATEARYRREGARFIFDVGTRLGLHYDTLATGIIYFHRFYMFHSFKQFPRYVTGACCLFLAGKVEETPKKCKDIIKTARSLLNDVQFGQFGDDPKEEVMVLERILLQTIKFDLQVEHPYQFLLKYAKQLKGDKNKIQKLVQMAWTFVNDSLCTTLSLQWEPEIIAVAVMYLAGRLCKFEIQEWTSKPMYRRWWEQFVQDVPVDVLEDICHQILDLYSQGKQQMPHHTPHQLQQPPSLQPTPQVPQVQQSQPSQSSEPSQPQQKDPQQPAQQQQPAQQPKKPSPQPSSPRQVKRAVVVSPKEENKAAEPPPPKIPKIETTHPPLPPAHPPPDRKPPLAAALGEAEPPGPVDATDLPKVQIPPPAHPAPVHQPPPLPHRPPPPPPSSYMTGMSTTSSYMSGEGYQSLQSMMKTEGPSYGALPPAYGPPAHLPYHPHVYPPNPPPPPVPPPPASFPPPAIPPPTPGYPPPPPTYNPNFPPPPPRLPPTHAVPPHPPPGLGLPPASYPPPAVPPGGQPPVPPPIPPPGMPPVGGLGRAAWMR | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 8 | Phosphorylation | MKENKENSSPSVTSA CCCCCCCCCCCCCCC | 44.72 | 23401153 | |
| 9 | Phosphorylation | KENKENSSPSVTSAN CCCCCCCCCCCCCCC | 32.54 | 23401153 | |
| 11 | Phosphorylation | NKENSSPSVTSANLD CCCCCCCCCCCCCCC | 39.72 | 22167270 | |
| 13 | Phosphorylation | ENSSPSVTSANLDHT CCCCCCCCCCCCCCC | 26.85 | 22167270 | |
| 14 | Phosphorylation | NSSPSVTSANLDHTK CCCCCCCCCCCCCCC | 17.01 | 22167270 | |
| 20 | Phosphorylation | TSANLDHTKPCWYWD CCCCCCCCCCCCCCC | 36.03 | 23403867 | |
| 25 | Phosphorylation | DHTKPCWYWDKKDLA CCCCCCCCCCHHHHC | 15.50 | 23403867 | |
| 34 | Phosphorylation | DKKDLAHTPSQLEGL CHHHHCCCHHHHCCC | 21.01 | 26074081 | |
| 36 | Phosphorylation | KDLAHTPSQLEGLDP HHHCCCHHHHCCCCH | 48.86 | 26074081 | |
| 166 (in isoform 3) | Ubiquitination | - | 45.36 | 21890473 | |
| 166 (in isoform 2) | Ubiquitination | - | 45.36 | 21890473 | |
| 166 (in isoform 1) | Ubiquitination | - | 45.36 | 21890473 | |
| 166 | Ubiquitination | HPYQFLLKYAKQLKG CHHHHHHHHHHHHCC | 45.36 | - | |
| 166 (in isoform 4) | Ubiquitination | - | 45.36 | 21890473 | |
| 226 | Phosphorylation | KFEIQEWTSKPMYRR HHHHHHHCCCHHHHH | 26.56 | 25690035 | |
| 227 | Phosphorylation | FEIQEWTSKPMYRRW HHHHHHCCCHHHHHH | 35.52 | 25690035 | |
| 231 | Phosphorylation | EWTSKPMYRRWWEQF HHCCCHHHHHHHHHH | 12.93 | 28509920 | |
| 324 | Phosphorylation | AQQPKKPSPQPSSPR CCCCCCCCCCCCCHH | 45.08 | 29255136 | |
| 328 | Phosphorylation | KKPSPQPSSPRQVKR CCCCCCCCCHHHCEE | 47.96 | 29255136 | |
| 329 | Phosphorylation | KPSPQPSSPRQVKRA CCCCCCCCHHHCEEE | 30.68 | 29255136 | |
| 340 | O-linked_Glycosylation | VKRAVVVSPKEENKA CEEEEECCHHHHCCC | 20.74 | 30379171 | |
| 340 (in isoform 1) | Phosphorylation | - | 20.74 | 27107777 | |
| 340 | Phosphorylation | VKRAVVVSPKEENKA CEEEEECCHHHHCCC | 20.74 | 29255136 | |
| 426 | Phosphorylation | RPPPPPPSSYMTGMS CCCCCCCHHHCCCCC | 39.62 | 24043423 | |
| 427 | Phosphorylation | PPPPPPSSYMTGMST CCCCCCHHHCCCCCC | 25.38 | 24043423 | |
| 428 | Phosphorylation | PPPPPSSYMTGMSTT CCCCCHHHCCCCCCC | 11.75 | 24043423 | |
| 430 | Phosphorylation | PPPSSYMTGMSTTSS CCCHHHCCCCCCCCC | 22.84 | 24043423 | |
| 433 | Phosphorylation | SSYMTGMSTTSSYMS HHHCCCCCCCCCCCC | 29.85 | 24043423 | |
| 434 | Phosphorylation | SYMTGMSTTSSYMSG HHCCCCCCCCCCCCC | 23.08 | 24043423 | |
| 435 | Phosphorylation | YMTGMSTTSSYMSGE HCCCCCCCCCCCCCC | 14.36 | 24043423 | |
| 436 | Phosphorylation | MTGMSTTSSYMSGEG CCCCCCCCCCCCCCC | 21.40 | 24043423 | |
| 437 | Phosphorylation | TGMSTTSSYMSGEGY CCCCCCCCCCCCCCH | 23.82 | 24043423 | |
| 438 | Phosphorylation | GMSTTSSYMSGEGYQ CCCCCCCCCCCCCHH | 8.62 | 24043423 | |
| 440 | Phosphorylation | STTSSYMSGEGYQSL CCCCCCCCCCCHHHH | 26.01 | 24043423 | |
| 444 | Phosphorylation | SYMSGEGYQSLQSMM CCCCCCCHHHHHHHH | 7.22 | 24043423 | |
| 446 | Phosphorylation | MSGEGYQSLQSMMKT CCCCCHHHHHHHHHC | 21.64 | 24043423 | |
| 449 | Phosphorylation | EGYQSLQSMMKTEGP CCHHHHHHHHHCCCC | 26.57 | 24043423 | |
| 580 | Methylation | LGRAAWMR------- CCCCHHCC------- | 32.46 | - |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of CCNK_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of CCNK_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| T22D4_HUMAN | TSC22D4 | physical | 16189514 | |
| CC85B_HUMAN | CCDC85B | physical | 16189514 | |
| NECA2_HUMAN | NECAB2 | physical | 16189514 | |
| USBP1_HUMAN | USHBP1 | physical | 16189514 | |
| FBLN4_HUMAN | EFEMP2 | physical | 16189514 | |
| KCNRG_HUMAN | KCNRG | physical | 16189514 | |
| RFX6_HUMAN | RFX6 | physical | 16189514 | |
| RBPMS_HUMAN | RBPMS | physical | 16189514 | |
| CEP76_HUMAN | CEP76 | physical | 16189514 | |
| RHXF2_HUMAN | RHOXF2 | physical | 16189514 | |
| KR412_HUMAN | KRTAP4-12 | physical | 16189514 | |
| HM20A_HUMAN | HMG20A | physical | 16189514 | |
| RPB1_HUMAN | POLR2A | physical | 9632813 | |
| CDK9_HUMAN | CDK9 | physical | 10574912 | |
| CDK12_HUMAN | CDK12 | physical | 22939629 | |
| NDC80_HUMAN | NDC80 | physical | 25416956 | |
| RBPMS_HUMAN | RBPMS | physical | 25416956 | |
| LZTS2_HUMAN | LZTS2 | physical | 25416956 | |
| CDK1_HUMAN | CDK1 | physical | 26344197 | |
| CDK12_HUMAN | CDK12 | physical | 26344197 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324; SER-328 ANDSER-340, AND MASS SPECTROMETRY. | |
| "A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-340, AND MASSSPECTROMETRY. | |
| "Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9; SER-324; SER-329 ANDSER-340, AND MASS SPECTROMETRY. | |
| "Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column."; Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.; Anal. Sci. 24:161-166(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-340, AND MASSSPECTROMETRY. | |
| "Improved titanium dioxide enrichment of phosphopeptides from HeLacells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra."; Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; J. Proteome Res. 6:4150-4162(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-329, AND MASSSPECTROMETRY. | |
| "Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-340, AND MASSSPECTROMETRY. | |
| "Large-scale characterization of HeLa cell nuclear phosphoproteins."; Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,Li J., Cohn M.A., Cantley L.C., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324 AND SER-329, ANDMASS SPECTROMETRY. | |